R H Begent
Overview
Explore the profile of R H Begent including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
1353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Turner N, Strauss S, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, et al.
Br J Cancer
. 2010 Mar;
102(7):1106-12.
PMID: 20234360
Background: The role of chemotherapy for neuroendocrine tumours remains controversial and there is no standard regimen. Method: We report the outcome for a consecutive series of chemonaive patients with metastatic...
3.
Maniaci V, Davidson B, Rolles K, Dhillon A, Hackshaw A, Begent R, et al.
Eur J Surg Oncol
. 2009 Jan;
35(6):617-21.
PMID: 19144491
Aim: We report the clinical outcome for a series of ten patients with fibrolamellar hepatocellular treated with resection followed by close surveillance and aggressive management of relapse. Methods: The case...
4.
Lieberman G, Maclean A, Buscombe J, Hilson A, Adamson K, REID W, et al.
BJOG
. 2002 Feb;
108(12):1229-36.
PMID: 11843384
Objective: To assess the effectiveness of a dual head coincidence gamma camera in identifying ovarian cancer as a less expensive alternative to the traditional 2-[18F] fluoro-2-deoxy-D-glucose (18FDG) system using positron...
5.
Flynn A, Pedley R, Green A, Boxer G, Boden R, Begent R
Cancer Biother Radiopharm
. 2002 Jan;
16(5):391-400.
PMID: 11776756
The biological effect of radioimmunotherapy (RIT) is most commonly assessed in terms of the absorbed radiation dose. In tumor, conventional dosimetry methods assume a uniform radionuclide and calculate a mean...
6.
Green A, Johnson C, Adamson K, Begent R
Phys Med Biol
. 2001 Jun;
46(6):1679-93.
PMID: 11419627
Antibody-targeted therapy of cancer has shown benefits in the treatment of some cancers but selective delivery has not been optimized. Many parameters influence antibody targeting; some will have a greater...
7.
Flynn A, Green A, Pedley R, Boxer G, Boden R, Begent R
Radiat Res
. 2001 Jun;
156(1):28-35.
PMID: 11418070
Flynn, A. A., Green, A. J., Pedley, R. B., Boxer, G. M., Boden, R. and Begent, R. H. J. A Mouse Model for Calculating the Absorbed Beta-Particle Dose from (131)I-...
8.
Pedley R, Hill S, Boxer G, Flynn A, Boden R, Watson R, et al.
Cancer Res
. 2001 Jun;
61(12):4716-22.
PMID: 11406542
Solid tumors have a heterogeneous pathophysiology, which has a major impact on therapy. Using SW1222 colorectal xenografts grown in nude mice, we have shown that antibody-targeted radioimmunotherapy (RIT) effectively treated...
9.
Webley S, Francis R, Pedley R, Sharma S, Begent R, Hartley J, et al.
Br J Cancer
. 2001 Jun;
84(12):1671-6.
PMID: 11401322
An antibody-directed enzyme prodrug therapy (ADEPT) system against CEA-positive tumours is currently in phase I clinical trials. It consists of a prodrug, 4-[N,N-bis(2-iodoethyl) amino] phenoxycarbonyl L -glutamic acid (ZD2767P) and...
10.
Flynn A, Boxer G, Begent R, Pedley R
Cancer Immunol Immunother
. 2001 Jun;
50(2):77-81.
PMID: 11401028
Antibody-directed cancer therapy has achieved encouraging responses despite poor localisation in tumour. This discrepancy may be attributed to heterogeneity of antibody delivery within tumours: preferential localisation in the better perfused...